Cargando…
Systematic identification of genomic markers of drug sensitivity in cancer cells
Clinical responses to anticancer therapies are often restricted to a subset of patients. In some cases, mutated cancer genes are potent biomarkers of response to targeted agents. To uncover new biomarkers of sensitivity and resistance to cancer therapeutics, we screened a panel of several hundred ca...
Ejemplares similares
-
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma
por: Gill, Sonja J., et al.
Publicado: (2015) -
A Landscape of Pharmacogenomic Interactions in Cancer
por: Iorio, Francesco, et al.
Publicado: (2016) -
Cell Model Passports—a hub for clinical, genetic and functional datasets of preclinical cancer models
por: van der Meer, Dieudonne, et al.
Publicado: (2019) -
Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011) -
A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical Translation
por: Nelson, Erik A., et al.
Publicado: (2011)